Composition comprising mir-499-5p activator for preventing or treating duchenne muscular dystrophy
AssigneesSamsung Life Public Welfare Foundation, Encell Co., Ltd.
InventorsJong Wook CHANG, Hong Bae JEON, Sang Eon PARK, Shin Ji OH, Jang Bin JEONG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a composition for preventing or treating Duchenne muscular dystrophy, including an miR-499-5p activator, wherein the miR-499-5p activator promotes expression of miR-499-5p by expressing MMP-1 in myotubes, and allows fibrous muscles to recover by down-regulating TGF-β receptor activation and smad2/3 phosphorylation. Thus, the composition can be used in the prevention or treatment of Duchenne muscular dystrophy.
Claims10
A method for treating Duchenne muscular dystrophy (DMD), comprising administering to a subject a pharmaceutical composition comprising a miR-499-5p activator.
(canceled)
A composition for diagnosing Duchenne muscular dystrophy, the composition comprising an agent that measures an expression level of miR-499-5p.
(canceled)
A method of providing information for diagnosis of Duchenne muscular dystrophy, the method comprising measuring an expression level of miR-499-5p in a sample of a subject.
Dependencies are inferred from the claim text.